HAYWARD,
Calif., Aug. 11, 2022 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that an abstract, entitled,
"Experience in Complex Outpatient Plastic Surgery Procedures Using
Sufentanil Sublingual Tablets" has been accepted for podium
presentation at Plastic Surgery: The Meeting 2022, taking
place October 27-30, 2022 in
Boston, MA.
The abstracts will be presented at the meeting and run from
Thursday, October 27, 2022 at
1:30 pm until Sunday, October 30, 2022 at 4:30 pm ET. The time of the podium presentation
is currently pending, but will be posted on the Investors/Events
section of the AcelRx website once that information becomes
available. The presentation will be conducted as in-person event
only with no virtual or replay option made available.
About Plastic Surgery: The Meeting 2022
Plastic Surgery: The Meeting brings together plastic
surgeons from countries around the globe. This annual event is the
premier educational and networking event of the year for both
domestic and international plastic surgeons, and is considered to
serve as the annual meeting of The American Society of Plastic
Surgeons (ASPS). ASPS is the largest plastic surgery specialty
organization in the world representing 94% of all board-certified
plastic surgeons in the U.S. including more than 11,000 plastic
surgeons worldwide. ASPS is considered a global institution and
leading authority on cosmetic and reconstructive plastic surgery.
The meeting also convenes members of The Plastic Surgery Foundation
(PSF), the American Society of Maxillofacial Surgeons (ASMS), and
the World Society for Simulation Surgery.
About DSUVIA (sufentanil sublingual tablet), 30
mcg
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in
certified medically supervised healthcare settings, such as
hospitals, surgical centers, and emergency departments, for the
management of acute pain severe enough to require an opioid
analgesic and for which alternative treatments are inadequate.
DSUVIA was designed to provide rapid analgesia via a non-invasive
route and to eliminate dosing errors associated with intravenous
(IV) administration. DSUVIA is a single-strength solid dosage form
administered sublingually via a single-dose applicator (SDA) by
healthcare professionals. Sufentanil is an opioid analgesic
previously only marketed for IV and epidural anesthesia and
analgesia. The sufentanil pharmacokinetic profile, when delivered
sublingually, avoids the high peak plasma levels and short duration
of action observed with IV administration. DZUVEO has been approved
by the European Medicines Agency and AcelRx's European
commercialization partner, Aguettant, will market the drug in
Europe.
This release is intended for investors only. For more
information, including important safety information and black box
warning for DSUVIA, please visit www.DSUVIA.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. The Company has one
approved product in the U.S., DSUVIA® (sufentanil sublingual
tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
several product candidates. The product candidates include:
Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg),
an investigational product in the U.S. being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings; two pre-filled, ready-to-use syringes of ephedrine and
phenylephrine licensed for the U.S. from Aguettant; Niyad™, a
regional anticoagulant for the extracorporeal circuit; and LTX-608,
for the potential treatment of COVID-19, disseminated intravascular
coagulation, acute respiratory distress syndrome and acute
pancreatitis. DZUVEO is an approved product in Europe.
This release is intended for investors only. For additional
information about AcelRx, please visit www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-abstract-acceptance-for-podium-presentation-at-plastic-surgery-the-meeting-2022-301603983.html
SOURCE AcelRx Pharmaceuticals, Inc.